ReviewCurrent rheumatology reports2016
Low-Dose IL-2 in the Treatment of Lupus.
Review in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared With Low-Dose Interleukin-2 in Systemic Lupus Erythematosus.Stem cells translational medicine · 2023Article
- Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells.Nature biomedical engineering · 2021Article
- Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.Frontiers in immunology · 2021Review
- Immunotherapy for Refractory Autoimmune Encephalitis.Frontiers in immunology · 2021Review
- Harnessing Tolerogenic Histone Peptide Epitopes From Nucleosomes for Selective Down-Regulation of Pathogenic Autoimmune Response in Lupus (Past, Present, and Future).Frontiers in immunology · 2021Review
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.Journal for immunotherapy of cancer · 2020Article
- IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.Journal of autoimmunity · 2019Article
- The role of FOXP3Clinical and experimental immunology · 2019Review
- Cellular Metabolic Regulation in the Differentiation and Function of Regulatory T Cells.Cells · 2019Review
- Novel Immunomodulatory Cytokine Regulates Inflammation, Diabetes, and Obesity to Protect From Diabetic Nephropathy.Frontiers in pharmacology · 2019Article
- Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.Frontiers in immunology · 2018Review
- Novel Treatments in Lupus.Frontiers in immunology · 2018Review
- New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Trends in molecular medicine · 2017Review
- T cells and autoimmune kidney disease.Nature reviews. Nephrology · 2017Review
- Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.Frontiers in immunology · 2017Review
- SLE-Associated Defects Promote Altered T Cell Function.Critical reviews in immunology · 2017Review
- Bacteriolytic Activity Of Human Interleukin-2, Chicken Egg Lysozyme In The Presence Of Potential Effectors.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent extensive research on interleukin-2 (IL-2)/IL-2 receptor (IL-2R) biology has revealed its critical role in the regulation of immune tolerance by influencing regulatory T (Treg) cell functions and survival. Since in vivo low-dose IL-2 administration in humans has been confirmed to be safe and effective in expanding Treg, it is likely that it may be considered for the treatment of several autoimmune diseases including systemic lupus erythematousus (SLE). A recent clinical trial demonstrated the safety and efficacy of low-dose IL-2 treatment on SLE. In SLE, T cells show aberrant function such as deficient IL-2 production and abnormal signaling events. Expansion of Treg by IL-2 represents a specific strategy to control self-tolerance; however, restoration of abnormal immune function and responses should be addressed more carefully in patients with SLE considering the complexity of disease etiology and pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.